| 1 | Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. (Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK) J Clin Oncol 2023 Nov 10;41(32):5049-5067 103 Citations |
| 1 | Lanreotide autogel/depot in advanced enteropancreatic neuroendocrine tumours: final results of the CLARINET open-label extension study. (Caplin ME, Pavel M, Phan AT, Ćwikła JB, Sedláčková E, Thanh XT, Wolin EM, Ruszniewski P, CLARINET Investigators) Endocrine 2021 Feb;71(2):502-513 81 Citations |
| 1 | Multidisciplinary management of acromegaly: A consensus. (Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S) Rev Endocr Metab Disord 2020 Dec;21(4):667-678 323 Citations |
| 1 | Effect of Lanreotide Depot/Autogel on Urinary 5-Hydroxyindoleacetic Acid and Plasma Chromogranin A Biomarkers in Nonfunctional Metastatic Enteropancreatic Neuroendocrine Tumors. (Pavel ME, Phan AT, Wolin EM, Mirakhur B, Liyanage N, Pitman Lowenthal S, Fisher GA Jr, Vinik AI, CLARINET Study Investigators) Oncologist 2019 Apr;24(4):463-474 17 Citations |
| 1 | Screening for comorbid conditions in patients enrolled in the SODA registry: a 2-year observational analysis. (Woodmansee WW, Gordon MB, Molitch ME, Ioachimescu AG, Carver DW, Mirakhur B, Cox D, Salvatori R) Endocrine 2018 Jul;61(1):105-117 7 Citations |
| 1 | A multicenter, observational study of lanreotide depot/autogel (LAN) in patients with acromegaly in the United States: 2-year experience from the SODA registry. (Salvatori R, Gordon MB, Woodmansee WW, Ioachimescu AG, Carver DW, Mirakhur B, Cox D, Molitch ME) Pituitary 2017 Dec;20(6):605-618 12 Citations |
| 1 | Recent advances in the management of gastroenteropancreatic neuroendocrine tumors: insights from the 2017 ASCO Gastrointestinal Cancers Symposium. (Iyer R, Phan AT, Boudreaux JP) Clin Adv Hematol Oncol 2017 Apr;15 Suppl 4(4):1-24 4 Citations |
| 2 | Calcium and Bone Turnover Markers in Acromegaly: A Prospective, Controlled Study. (Constantin T, Tangpricha V, Shah R, Oyesiku NM, Ioachimescu OC, Ritchie J, Ioachimescu AG) J Clin Endocrinol Metab 2017 Jul 01;102(7):2416-2424 45 Citations |
| 1 | Neuroendocrine Tumors and Lanreotide Depot: Clinical Considerations and Nurse and Patient Preferences. (Ryan P, Phan AT, Adelman DT, Iwasaki M) Clin J Oncol Nurs 2016 Dec 01;20(6):E139-E146 8 Citations |
| 1 | Late-night salivary cortisol may be valuable for assessing treatment response in patients with Cushing's disease: 12-month, Phase III pasireotide study. (Findling JW, Fleseriu M, Newell-Price J, Petersenn S, Pivonello R, Kandra A, Pedroncelli AM, Biller BM) Endocrine 2016 Nov;54(2):516-523 26 Citations |
| 1 | Lanreotide Depot: An Antineoplastic Treatment of Carcinoid or Neuroendocrine Tumors. (Wolin EM, Manon A, Chassaing C, Lewis A, Bertocchi L, Richard J, Phan AT) J Gastrointest Cancer 2016 Dec;47(4):366-374 31 Citations |
| 1 | Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P, CLARINET Investigators) Endocr Relat Cancer 2016 Mar;23(3):191-9 229 Citations |
| 1 | Neuronostatin acts via GPR107 to increase cAMP-independent PKA phosphorylation and proglucagon mRNA accumulation in pancreatic α-cells. (Elrick MM, Samson WK, Corbett JA, Salvatori AS, Stein LM, Kolar GR, Naatz A, Yosten GL) Am J Physiol Regul Integr Comp Physiol 2016 Jan 15;310(2):R143-55 41 Citations |
| 1 | New and Emerging Treatment Options for Gastroenteropancreatic Neuroendocrine Tumors. (Phan AT, Kunz PL, Reidy-Lagunes DL) Clin Adv Hematol Oncol 2015 May;13(5 Suppl 5):1-18; quiz 1 p following 18 8 Citations |
| 1 | Hypermethylation of BDNF and SST Genes in the Orbital Frontal Cortex of Older Individuals: A Putative Mechanism for Declining Gene Expression with Age. (McKinney BC, Lin CW, Oh H, Tseng GC, Lewis DA, Sibille E) Neuropsychopharmacology 2015 Oct;40(11):2604-13 28 Citations |
| 1 | Advances in the treatment of gastroenteropancreatic neuroendocrine tumors. (Phan AT) Clin Adv Hematol Oncol 2014 Dec;12(12 Suppl 19):3-5 2 Citations |
| 1 | Lanreotide in metastatic enteropancreatic neuroendocrine tumors. (Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P, CLARINET Investigators) N Engl J Med 2014 Jul 17;371(3):224-33 1325 Citations |
| 1 | Neuronostatin inhibits glucose-stimulated insulin secretion via direct action on the pancreatic α-cell. (Salvatori AS, Elrick MM, Samson WK, Corbett JA, Yosten GL) Am J Physiol Endocrinol Metab 2014 Jun 01;306(11):E1257-63 25 Citations |
| 1 | Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing's disease: results from a Phase III study. (Pivonello R, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Trovato A, Hughes G, Salgado LR, Lacroix A, Schopohl J, Biller BM, Pasireotide B2305 Study Group) Clin Endocrinol (Oxf) 2014 Sep;81(3):408-17 113 Citations |
| 1 | High variability in baseline urinary free cortisol values in patients with Cushing's disease. (Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Sen K, Salgado LR, Colao A, Biller BM, Pasireotide B2305 Study Group) Clin Endocrinol (Oxf) 2014 Feb;80(2):261-9 140 Citations |
| 1 | Synaptic relationship between somatostatin- and neurokinin-1 receptor-immunoreactive neurons in the pre-Bötzinger complex of rats. (Wei XY, Zhao Y, Wong-Riley MT, Ju G, Liu YY) J Neurochem 2012 Sep;122(5):923-33 19 Citations |
| 1 | A 12-month phase 3 study of pasireotide in Cushing's disease. (Colao A, Petersenn S, Newell-Price J, Findling JW, Gu F, Maldonado M, Schoenherr U, Mills D, Salgado LR, Biller BM, Pasireotide B2305 Study Group) N Engl J Med 2012 Mar 08;366(10):914-24 |
| 1 | Evidence for a role of opioids in epoxyeicosatrienoic acid-induced cardioprotection in rat hearts. (Gross GJ, Baker JE, Hsu A, Wu HE, Falck JR, Nithipatikom K) Am J Physiol Heart Circ Physiol 2010 Jun;298(6):H2201-7 31 Citations |
| 1 | Surgical treatment of non-functioning pancreatic islet cell tumors. (Kouvaraki MA, Solorzano CC, Shapiro SE, Yao JC, Perrier ND, Lee JE, Evans DB) J Surg Oncol 2005 Mar 01;89(3):170-85 65 Citations |
| 1 | Serum prostate-specific antigen concentration is increased in acromegalic women. (Manetti L, Lupi I, Genovesi M, Morselli L, Grasso L, Nencetti C, Gasperi M, Bogazzi F, Bartalena L, Martino E) J Endocrinol Invest 2004;27(7):643-7 3 Citations |
| 1 | Hypoalgesia elicited by a conditioned stimulus is blocked by a mu, but not a delta or a kappa, opioid antagonist injected into the rostral ventromedial medulla. (Foo H, Helmstetter FJ) Pain 1999 Dec;83(3):427-431 26 Citations |
| 1 | Activin A and follistatin expression in developing targets of ciliary ganglion neurons suggests a role in regulating neurotransmitter phenotype. (Darland DC, Link BA, Nishi R) Neuron 1995 Oct;15(4):857-66 46 Citations |
| 1 | Differential effects of selective opioid peptide antagonists on the acquisition of pavlovian fear conditioning. (Fanselow MS, Kim JJ, Young SL, Calcagnetti DJ, DeCola JP, Helmstetter FJ, Landeira-Fernandez J) Peptides 1991;12(5):1033-7 48 Citations |
| 1 | Role of mu and kappa opioid receptors in conditional fear-induced analgesia: the antagonistic actions of nor-binaltorphimine and the cyclic somatostatin octapeptide, Cys2Tyr3Orn5Pen7-amide. (Fanselow MS, Calcagnetti DJ, Helmstetter FJ) J Pharmacol Exp Ther 1989 Sep;250(3):825-30 60 Citations |
